Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations

American Journal of Respiratory and Critical Care Medicine

Volumn 178, Issue 11, 2008, Pages 1139-1147

  Seemungal, Terence A R ^a,b   Wilkinson, Tom M A ^b   Hurst, John R ^b   Perera, Wayomi R ^b   Sapsford, Ray J ^b   Wedzicha, Jadwiga A ^b,c  

^a UNIVERSITY OF THE WEST INDIES   (Trinidad and Tobago)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Chronic obstructive pulmonary disease exacerbation; Exacerbation frequency; FEV1; Macrolide

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT; C REACTIVE PROTEIN; ERYTHROMYCIN STEARATE; INTERLEUKIN 6; INTERLEUKIN 8; MUSCARINIC RECEPTOR BLOCKING AGENT; MYELOPEROXIDASE; PLACEBO; PREDNISOLONE; STEROID; THEOPHYLLINE;

ABDOMINAL CRAMP; ADULT; AGED; ARTICLE; BACTERIAL FLORA; BACTERIOLOGY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DYSPEPSIA; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; SPUTUM EXAMINATION; TREATMENT OUTCOME; VOMITING;

AGED; ANTIBIOTIC PROPHYLAXIS; DOUBLE-BLIND METHOD; ERYTHROMYCIN; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INFLAMMATION; KAPLAN-MEIERS ESTIMATE; MACROLIDES; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPUTUM;

EID: 56749157688     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200801-145OC     Document Type: Article

References (45)

1. Strachan DP. Epidemiology: a British perspective. In: Calverley PMA, Pride NB, editors. Chronic obstructive pulmonary disease. London: Chapman & Hall; 1995. pp. 57-62.
2. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60:925-931.
3. Seemungal T, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-1422.
4. Bhowmik ST, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and physiological changes at COPD exacerbations. Thorax 2000;55:114-120.
5. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. The relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-852.
6. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-789.
7. Keatings VM, Jatakanon A, Wordsell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997;155:542-548.
8. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe COPD: the ISOLDE trial. BMJ 2000;320:1297-1303.
9. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-1909.
10. Barnes NC, Qiu Y, Pavord ID, Parker D, Davis PA, Zhu J, Johnson M, Thomson NC, Jeffery PK; on behalf of the SCO30005 Study Group. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006;173:736.
11. Bourbeau J, Christodoulopoulos P, Maltais F, Yamauchi Y, Olivenstein R, Hamid Q. Chronic obstructive pulmonary disease: effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax 2007;62:938-943.
12. Peckham DG. Macrolide antibiotics and cystic fibrosis. Thorax 2002;57:189-190.
13. Ishizawa K, Suzuki T, Yamaya M, Jia YX, Kobayashi S, Ida S, Kubo H, Sekizawa K, Sasaki H. Erythromycin increases bactericidal activity of surface liquid in human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2005;289:L565-L573.
14. Hoiby H. Diffuse panbronchiolitis and cystic fibrosis: East meets West. Thorax 1994;49:531-532.
15. Seemungal TAR, Harper-Owen R, Bhowmik A, Moric I, Sanderson G, Message S, MacCallum P, Meade TW, Jeffries DJ, Johnston SL, et al. Symptoms, inflammatory markers and respiratory viruses in acute exacerbations and stable COPD. Am J Respir Crit Care Med 2001;164:1618-1623.
16. Suzuki T, Yamaya M, Sekizawa K, Hosoda M, Yamada N, Ishizuka S, Yoshino A, Yasuda H, Takahashi H, Nishimura H, et al. Erythromycin inhibits rhinovirus infection in cultured human tracheal epithelial cells. Am J Respir Crit Care Med 2002;165:1113-1118.
17. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomized trial. Thorax 2002;57:212-216.
18. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002;360:978-984.
19. Seemungal TAR, Wilkinson TMA, Perera W, Hurst JR, Wedzicha JA. Long term macrolide therapy decreases exacerbations in COPD [abstract]. Am J Respir Crit Care Med 2007;175(Suppl):A764.
20. Wilkinson TMA, Seemungal TAR, Sapsford R, Hurst JR, Perera W, Wedzicha JA. Effect of long term erythromycin in COPD trial (ELECT): exacerbations and inflammation [abstract]. Thorax 2007;62(Suppl 3):S115.
21. Seemungal TAR, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608-1618.
22. Patel SI, Seemungal TAR, Wilks M, Lloyd-Owen S, Donaldson GC, Wedzicha JA. Relation of bacterial colonisation and the frequency, character and severity of COPD exacerbations. Thorax 2002;57:759-764.
23. Andrews JM; for the BSAC Working Party on Susceptibility Testing. BSAC standardized disc susceptibility testing method (version 4). J Antimicrob Chemother 2005;56:60-76.
24. Haydon RC, Thelin JW, Davis WE. Erythromycin ototoxicity: analysis and conclusions based on 22 case reports. Otolaryngol Head Neck Surg 1984;92:678-684.
25. Swanson DJ, Sung RJ, Fine MJ, Orloff JJ, Chu SY, Yu VL. Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia. Am J Med 1992;92:61-68.
26. Davis KK, Kao PN, Jacobs SS, Ruoss SJ. Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series. BMC Pulm Med 2007;7:2.
27. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998;157:1829-1832.
28. Takeda H, Miura H, Kawahira M, Takeda H, Miura H, Kawahira M, Kobayashi H, Otomo S, Nakaike S. Long-term administration study on TE-031 (A-56268) in the treatment of diffuse panbronchiolitis. Kansenshogaku Zasshi 1989;63:71-78.
29. Yamamoto M, Kondo A, Tamura M, Izumi T, Ina Y, Noda M. Long-term therapeutic effects of erythromycin and new quinolone antibacterial agents on diffuse panbronchiolitis. Nihon Kyobu Shikkan Gakkai Zasshi 1990;28:1305-1313.
30. Kobayashi H, Takeda H, Sakayori S, Kawakami Y, Otsuka Y, Tamura M, Konishi K, Tanimoto S, Fukakusa M, Shimada K. Study on azithromycin in treatment of diffuse pan-bronchiolitis. Kansenshogaku Zasshi 1995;69:711-712.
31. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW III; Macrolide Study Group. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290:1749-1756.
32. Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais J-P. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 2006;61:895-902.
33. Seemungal TAR, Harper-Owen R, Bhowmik A, Jeffries DJ, Wedzicha JA. Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease. Eur Respir J 2000;16:677-683.
34. Rohde G, Wiethege A, Borg I, Kauth M, Bauer TT, Gillissen A, Bufe A, Schultze-Werninghaus G. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax 2003;58:37-42.
35. Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, Fabbri LM, Johnston SL. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006;173:1114-1121.
36. Suzuki T, Yanai M, Yamaya M, Satoh-Nakagawa T, Sekizawa K, Ishida S, Sasaki H. Erythromycin and common cold in COPD. Chest 2001;120:730-733.
37. 2 agonists) Study Group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-456.
38. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins C, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM. Effect of pharmacotherapy on rate of decline of lung function in COPD: results from the TORCH Study. Am J Respir Crit Care Med 2008;178:332-338.
39. 1 decline in current smokers but not ex-smokers with mild chronic obstructive lung disease: results from the Lung Health Study. Am J Respir Crit Care Med 2001;164:358-364.
40. Tramper-Stranders GA, van der Ent CK, Gerritsen SA, Fleer A, Kimpen JL, Wolfs TF. Macrolide-resistant Staphylococcus aureus colonization in cystic fibrosis patients: is there transmission to household contacts? Pediatr Infect Dis J 2007;60:665-668.
41. Jang YJ, Kwon H-J, Lee BJ. Effects of clarithromycin on rhinovirus-16 infection in A549 cells. Eur Respir J 2006;27:12-19.
42. Labro MT, Abdelghaffer H. Immunomodulation by macrolide antibiotics. J Chemother 2001;13:3-8.
43. Hodge S, Hodge G, Jersmann H, Matthews G, Ahern J, Holmes M, Reynolds PN. Azithromycin improves macrophage phagocytic function and expression of mannose receptor in COPD Am J Respir Crit Care Med 2008;178:139-148.
44. Blasi F, Damato S, Cosentini R, Tarsia P, Raccanelli R, Centanni S, Allegra L; Chlamydia InterAction with COPD (CIAC) Study Group. Chlamydia pneumoniae and chronic bronchitis: association with severity and bacterial clearance following treatment. Thorax 2002;57:672-676.
45. Hattotuwa KL, Gizycki MJ, Tareq K, Ansari W, Jeffery PK, Barnes NC. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002;165:1592-1596.